A 19-year-old Canadian man becomes the first human cured through prime gene editing after doctors corrected a rare genetic ...

Prime Medicine's application will test an FDA that has promised to speed new gene-editing treatments but has recently spurned ...

Using prime editing, NCF1 mutation is corrected in a 19-year-old with chronic granulomatous disease, an inherited immune disorder, marking a gene therapy milestone.

The prime editor is a fusion protein consisting of a catalytically impaired Cas9 nickase (Cas9n) and an engineered reverse transcriptase (RT). The Cas9n is guided by a prime editing guide RNA (pegRNA) ...

Add Yahoo as a preferred source to see more of our stories on Google. Prime Medicine will test its gene editing technology as treatment for a rare liver and lung disorder, revealing on Tuesday plans ...

Prime Medicine, a biotech company that set out to use its more precise approach to gene editing to develop new one-time treatments for rare diseases, is expanding its scope to more prevalent ...

The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the ...

Prime Medicine, Inc. develops prime editing technologies but lacks proof of concept data despite being in the market for 6 years and IPO for 3 years. The gene editing sector is highly risky, with poor ...

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented ...